

Ref: 21411/0240/001-0001

Date: 11.11.2019

Medicines and Healthcare products Regulatory Agency  
10 S Colonnade,  
Canary Wharf,  
London,  
E14 4PU

Castle Hill Hospital  
Castle Road  
Cottingham  
East Yorkshire  
HU16 5JQ

Tel: 01482 461903  
Email: james.illingworth@hey.nhs.uk

Dear MHRA

<b>Trial title:</b> RAMIPRIL: A double-blind, randomised controlled trial of percutaneous transluminal angioplasty (PTA) & Ramipril versus PTA & placebo in the management of intermittent claudication (IC).		
<b>EudraCT no:</b> 2012-005449-19	<b>IRAS project ID:</b> 113453	<b>Sponsor R&amp;D ref no:</b> R1511
<b>Participating site:</b> Hull Royal Infirmary, Anlaby Road, Hull, HU3 2JZ		<b>Principal investigator:</b> Mr Augustine Smithies

This is to notify you that the above study terminated early with no sufficient data to analyse.

Unfortunately recruitment was much lower than expected as approximately 80% of patients were on an ACE Inhibitor (anticipated to be 20% when designing the study). Thus the trial would have required an extension both in time and funding. The decision was taken that this would not be feasible and the study was terminated.

Yours sincerely



**James Illingworth**  
R&D Manager